Health officials in Italy have confirmed that a South African national in isolation in Padova has tested negative for the Andes hantavirus, providing a significant sigh of relief for public health authorities monitoring a rare and potentially lethal pathogen. The patient, a 50-year-old professional from Johannesburg, had been placed under strict surveillance after being identified as a contact of a traveler who succumbed to the virus.
The news was delivered by Maria Rosaria Campitiello, Director of the Prevention Department at the Ministry of Health, who noted that while the negative test is a promising sign, the patient remains under observation. Because the virus can have a variable incubation period, the current result does not entirely rule out a future positive status, though the fact that the patient remains entirely asymptomatic is a strong clinical indicator of health.
The case sparked an intensive international coordination effort, involving the Usl Euganea local health authority, the Italian Ministry of Health, and the IRCCS Spallanzani National Institute for Infectious Diseases in Rome. The situation underscores the complexities of managing zoonotic diseases—pathogens that jump from animals to humans—in an era of global travel.
The Chain of Contact: From Patagonia to Padova
The health scare began with Mirjam Schilperoord, a 69-year-old Dutch woman who contracted the Andes hantavirus during a trip to Patagonia. The virus is endemic to South America, primarily transmitted to humans through contact with the excreta of infected long-tailed pygmy rice rats. Ms. Schilperoord unfortunately passed away due to the infection.
The South African patient had been on the same flight as Ms. Schilperoord, landing in Venice on April 26. Although the two were separated by several meters and their interaction was minimal, public health protocols required the man to be monitored. He was placed in fiduciary isolation in Padova on May 9.
Medical officials categorized the man as a “low-risk contact.” Under the direction of Dr. Luca Sbrogiò, head of the Prevention Department at Usl Euganea, the patient was placed under active surveillance, which included scheduled check-ins with health operators to monitor for any emerging symptoms.
| Date | Event | Status/Action |
|---|---|---|
| April 26 | Arrival in Venice | Patient lands; initial contact with index case occurred on flight. |
| May 9 | Isolation Begins | Patient moved to fiduciary isolation in Padova. |
| May 11 | Testing Phase | Blood samples collected by hygiene and public health services. |
| May 11 (Eve) | Result Confirmed | Test returns negative; patient remains asymptomatic. |
Understanding the Andes Hantavirus
As a physician, it is important to clarify why the Andes strain caused more concern than other hantaviruses. Most hantaviruses are transmitted strictly from rodents to humans. However, the Andes virus (ANDV) is one of the few strains known to exhibit human-to-human transmission, typically occurring through close, prolonged contact.
The virus targets the respiratory system, leading to Hantavirus Pulmonary Syndrome (HPS). The progression is often rapid and severe:
- Early Stage: Patients typically present with flu-like symptoms, including fever, cough, severe joint pain, and muscle aches.
- Critical Stage: The condition can degenerate into cardiopulmonary edema, where the lungs fill with fluid, leading to severe respiratory distress.
- Outcome: Without intensive supportive care, the resulting cardiopulmonary hemorrhages can be fatal.
Professor Francesco Vaia, former director of the Spallanzani Institute and former prevention lead at the Ministry of Health, emphasized that there is currently no vaccine for the Andes hantavirus. There are no specific antiviral drugs designed to eliminate the virus from the body. Treatment is entirely supportive, focusing on managing the symptoms and maintaining respiratory function through mechanical ventilation if necessary.
A Specialized Diagnostic Response
The rigor of the testing process reflects the danger of the pathogen. Blood samples were not processed locally but were transported via a dedicated vehicle and two specialized drivers from Usl Euganea to the IRCCS Spallanzani in Rome. The Spallanzani’s Virology Laboratory is the European Commission’s designated reference center for emerging zoonotic viral pathogens carried by rodents.
The laboratory employed both serological and molecular tests to detect the presence of the virus or specific antibodies. This dual approach ensures that the virus is not missed, whether it is currently replicating in the blood or if the body has already begun producing an immune response.
Public Health Advice and Prevention
While the risk of human-to-human transmission is rare—requiring the exchange of droplets (saliva) or aerosols (tiny particles emitted during coughing or sneezing)—the primary threat remains the environment. Professor Vaia has used this incident to urge city mayors, particularly in metropolitan areas, to strengthen rodent control measures.
To minimize the risk of hantavirus infection, health experts recommend:
- Avoiding areas heavily infested with rodents.
- Using caution when cleaning sheds, cabins, or garages that may contain rodent droppings (avoiding sweeping or vacuuming, which can stir up viral aerosols).
- Ensuring food is stored in rodent-proof containers.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. If you suspect you have been exposed to a zoonotic disease or are experiencing respiratory distress, please contact a healthcare provider or your local public health department immediately.
The patient in Padova will remain under the guidance of the Ministry of Health and regional authorities until the formal surveillance period concludes. The next checkpoint will involve a final review of the patient’s clinical status by the Usl Euganea before the isolation order is officially lifted.
Do you have questions about zoonotic diseases or public health protocols? Share this article and let us know in the comments.
